NT-proBNP in Acute Dyspnea: Effects on Treatment, Hospitalisation and Costs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00410293|
Recruitment Status : Completed
First Posted : December 12, 2006
Last Update Posted : December 12, 2006
Diagnostic uncertainty in patients with complaints of shortness of breath presenting to the Emergency Department of a hospital may delay treatment and proper care. In patients with shortness of breath due to heart failure increased plasma levels of NT-pro-B-type natriuretic peptide (NT-proBNP) can be demonstrated. The use of NT-proBNP as a biomarker for heart failure in patients presenting to the emergency department with dyspnea might improve care and reduce length of hospital stay.
To investigate the effect of NT-proBNP testing on patient care and time to discharge the NT-proBNP test will be randomized. In patients in the study group, the NT-proBNP plasma level is determined at admission and the physician in charge will immediately receive the result of the test. In patients in the control group blood will be sampled but the physician will recieve no information on the NT-proBNP plasma level.
In our study we will investigate the effect of introduction of NT-proBNP as biomarker for heart failure on treatment, time to discharge and costs.
|Condition or disease||Intervention/treatment|
|Heart Failure Dyspnea||Procedure: NT-proBNP testing|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||500 participants|
|Intervention Model:||Single Group Assignment|
|Official Title:||NT-proBNP Testing in Patients Presenting to the Emergency Department With Acute Dyspnea: Evaluation of Effects on Treatment, Hospitalisation Rate and Costs|
|Study Start Date :||December 2004|
|Estimated Study Completion Date :||August 2006|
- Time to discharge
- Cost of treatment
- Duration of stay at the ED
- Proportion of patients admitted to the hospital
- Proportion of patients admitted to an intensive or coronary care unit
- Specialist consultations
- Medical treatment
- Diagnostic investigations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00410293
|Rotterdam, Netherlands, 3015 CE|
|Principal Investigator:||Anton H. van den Meiracker, MD, PhD||Erasmus MC, Rotterdam, the Netherlands|